title: [Adipocytokines: implications in the prognosis and drug treatment of cardiovascular diseases].
abstract: Adipocytokines, fat tissue derived factors with regulatory properties, are involved in the pathophysiology of atheromatous and metabolic illnesses such as: ischemic heart disease, insulin resistance, obesity, dyslipidemia and diabetes mellitus. Enlargement of visceral adipose tissue depots determines a worse evolution for those complaints. Drugs as angiotensin converting enzyme inhibitors (ACEI), thiazolidinediones (glitazones) or angiotensin-II receptor antagonists, generally associated with the adequate hypolipidemic (statins, fibrates) or antiobesity (orlistat, sibutramine, rimonabant) medication, would increase those adipocytokines with anti-inflammatory and insulin-sensitizing properties (i.e. adiponectin or visfatin), while reducing pro-inflammatory and thrombogenic cytokines (as leptin, tumor necrosis factor [TNF]-alpha, plasminogen activator inhibitor 1 [PAI-1]). Thus, these pharmacologic therapeutic approaches would have a beneficial effect in order to diminish morbidity-mortality and improve the prognosis of patients with said diseases, all of them related to high cardiovascular risk.
authors.affiliation: Departamento de Fisiología y Farmacología, Facultad de Medicina, Universidad de Salamanca, Salamanca, Spain. mcio@usal.es
authors.forename: M C
authors.initials: MC
authors.lastname: Iglesias-Osma
authors.forename: M A
authors.initials: MA
authors.lastname: Torres
authors.forename: M J
authors.initials: MJ
authors.lastname: García-Barrado
authors.forename: J
authors.initials: J
authors.lastname: Moratinos
mesh_terms: D054392:Adipokines / Q000502:physiology*; D052242:Adiponectin / Q000502:physiology; D000273:Adipose Tissue / Q000502:physiology; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D011379:Prognosis; D012307:Risk Factors
chemical_list: D054392:Adipokines; D052242:Adiponectin